Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Evaluating the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics and Curative Effect of Dose Escalation and Extension for Single Drug TJ004309 and Toripalimab Combine Treatment for Advanced Solid Tumor

NCT04322006 is registered in ClinicalTrials.gov with TJ Biopharma Co., Ltd. as lead sponsor.

NCT NCT04322006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04322006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Evaluating the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics and Curative Effect of Dose Escalation and Extension for Single Drug TJ004309 and Toripalimab Combine Treatment for Advanced Solid Tumor
Lead sponsor
TJ Biopharma Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
May 9, 2020
Completion date
April 30, 2025
Enrollment
225 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor